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Abstract
Background: Previous work in HEK-293 cells demonstrated the importance of amino acid-induced mTORC1 translocation to the lysosomal surface for stimulating mTORC1 kinase activity and protein synthesis. This study tested
the conservation of this amino acid sensing mechanism in human skeletal muscle by treating subjects with chloroquine—a lysosomotropic agent that induces in vitro and in vivo lysosome dysfunction.
Methods: mTORC1 signaling and muscle protein synthesis (MPS) were determined in vivo in a randomized controlled trial of 14 subjects (10 M, 4 F; 26 ± 4 year) that ingested 10 g of essential amino acids (EAA) after receiving
750 mg of chloroquine (CHQ, n = 7) or serving as controls (CON, n = 7; no chloroquine). Additionally, differentiated
C2C12 cells were used to assess mTORC1 signaling and myotube protein synthesis (MyPS) in the presence and
absence of leucine and the lysosomotropic agent chloroquine.
Results: mTORC1, S6K1, 4E-BP1 and rpS6 phosphorylation increased in both CON and CHQ 1 h post EAA ingestion
(P < 0.05). MPS increased similarly in both groups (CON, P = 0.06; CHQ, P < 0.05). In contrast, in C2C12 cells, 1 mM leucine increased mTORC1 and S6K1 phosphorylation (P < 0.05), which was inhibited by 2 mg/ml chloroquine. Chloroquine (2 mg/ml) was sufficient to disrupt mTORC1 signaling, and MyPS.
Conclusions: Chloroquine did not inhibit amino acid-induced activation of mTORC1 signaling and skeletal MPS in
humans as it does in C2C12 muscle cells. Therefore, different in vivo experimental approaches are required for confirming the precise role of the lysosome and amino acid sensing in human skeletal muscle.
Trial registration NCT00891696. Registered 29 April 2009.
Keywords: Amino acid sensing, Muscle protein turnover, mTOR signaling, Chloroquine
Background
Various anabolic stimuli facilitate muscle growth through
the stimulation of the mechanistic target of rapamycin complex 1 (mTORC1). In particular, activation of
mTORC1 results in the induction of a signaling cascade
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that promotes the enhancement of protein initiation and
translation [1–3]. While ingestion of protein or amino
acids has been shown to result in increases in skeletal
muscle protein synthesis in animal and human models
[4–8], the precise mechanism(s) through which amino
acids activate mTORC1 is less understood.
An increase in amino acid availability within the cell
shifts the environment from a catabolic to an anabolic
state. During catabolism, mTORC1 is inactive. The inactive state of mTORC1 coincides with an upregulation of
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autophagy through the lysosomal degradation pathway
[9]. This increase in autophagy provides amino acids that
may be converted into energy-yielding substrates during
periods of low energy availability. Conversely, during the
anabolic state, autophagy is suppressed, and the lysosome
becomes an integral component in the synthesis of new
proteins via mTORC1 activation [10].
Recent work in human embryonic kidney cells (HEK)
has identified important molecular processes through
which amino acids are “sensed” at the cellular level.
During periods of low energy availability, mTORC1 is
inactive and the GATOR1 protein complex serves as a
GTPase-activating protein (GAP) to inactivate Rag A/B
proteins located on the surface of the lysosome. These
Rag proteins, in a GDP-bound state, prevent localization
of mTORC1 to the lysosome [11, 12]. On the other hand,
increased amino acid availability within the cell activates
the amino acid sensing machinery upon introduction of
the amino acids into the lysosome. The arginine transporter SLC38A9 may be the first amino acid transporter
identified that signals availability of amino acids to the
lysosome [13, 14]. Once amino acids are “sensed” by the
cell, GATOR1 action is inhibited via GATOR2 activation
through a mechanism by which Sestrin 2 serves as a leucine sensor [15, 16]. This allows for the Rag proteins to
switch from a GDP-bound state to a GTP-bound state.
The Rag A/C heterodimer becomes active in the GTPbound state and then recruits the mTORC1 complex to
bind to the lysosome. This colocalization of mTORC1
and the lysosome initiates the mTORC1 signaling cascade [12] resulting in a stimulation of protein synthesis
during amino acid sufficiency [17].
The mechanism of amino acid sensing via mTOR/
lysosomal colocalization was discovered in HEK cells.
Whether a similar mechanism is responsible for activating mTORC1 in the presence of increased amino acid
availability within human skeletal muscle is not known. A
substantial amount of research has demonstrated the link
between protein or amino acid ingestion and increases
in skeletal muscle protein synthesis. To this point, these
studies have been descriptive in nature. This proposed
mechanism could shed light on the long-sought mechanism bridging the gap between amino acid ingestion
and mTOR pathway-activated protein synthesis. Currently there is evidence to suggest that colocalization of

mTORC1 and the lysosome occurs in skeletal muscle in
the presence of amino acids [18, 19] We were intrigued
by the drug chloroquine, a lysosomotropic agent that
causes lysosomal dysfunction in vivo, as to whether it
would be a useful pharmacological intervention to test
the role of the lysosome in amino acid sensing in human
skeletal muscle. Therefore, we hypothesized that amino
acid-induced activation of mTORC1 signaling and muscle protein synthesis would be inhibited by the administration of chloroquine. To test our hypothesis, we
employed a randomized controlled human trial followed
by an in vitro cell culture study.

Methods
Clinical trial
Screening of participants

We recruited fourteen healthy, men and women
18–40 years of age for this randomized clinical trial. Participant characteristics are shown in Table 1.
The participants were recruited through flyers, newspaper advertisements, and word of mouth (Fig. 1). Participants were required to be healthy, only recreationally
active, nonsmoking, with a body mass index < 30. Participants were screened at the Institute for Translational
Sciences-Clinical Research Center (ITS-CRC) at the University of Texas Medical Branch. The screening included:
laboratory tests (complete blood count with differential,
liver and kidney function tests, coagulation profile, fasting blood glucose, hepatitis B and C screening, HIV test,
thyroid stimulating hormone, lipid profile, urinalysis, and
drug screening), clinical history with physical exam, and
a dual-energy X-ray absorptiometry (DXA) scan (Lunar
iDXA, GE Healthcare, Madison, WI) for measuring lean
and fat mass. All participants provided written informed
consent before enrollment in the study. The study was
approved by the Institutional Review Board of the University of Texas Medical Branch, and is in compliance
with the Declaration of Helsinki as revised in 1983.
Study design

In a randomized controlled trial, subjects were randomized to either a control or treatment group, control
(N = 7 Con) or chloroquine (N = 7 CHQ). Both groups
completed an identical experimental trial (see below)
with the exception of the treatment group receiving

Table 1 Subject characteristics
N

Gender

CON

7

5 M, 2F

CHQ

7

5 M, 2F

Data are mean ± SEM

Age, years
24.9 ± 1.5

26.9 ± 1.9

BMI, kg/m2
22.0 ± 0.8

23.0 ± 1.0

Fat %
21.3 ± 2.1

22.0 ± 2.2

Lean Mass, kg
47.4 ± 2.9

50.3 ± 4.1
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Fig. 1 Consort flow diagram for study recruitment

chloroquine prior to ingesting EAA (Fig. 2). One subject per group was excluded from the results due to an
inability to retrieve a muscle sample during the third
biopsy. Enrolled participants reported to the ITSCRC at ~ 1800 h the night before the study. Participants refrained from exercise for at least 48 h prior to
admission. Participants were fed a standardized dinner (10 kcal/kg of body weight; 60% carbohydrate, 20%
fat, and 20% protein) and a snack at 2100 h (5 kcal/kg of
body weight; 60% carbohydrate, 20% fat, and 20% protein), and asked to sleep in the UTMB CRC. After 2300 h,
they were allowed only water until the completion of the
experimental trial. CHQ subjects ingested a 250 mg dose
of chloroquine at 2000 h the night before the study and
a 500 mg dose the next morning following commencement of the stable isotope tracers consistent with De feo
et al. [20]. Control subjects received nothing. No placebo
pill was given as it seemed unnecessary as the subjects
remained in bed for the duration of the study and could
not manipulate the outcome measures of this study via a
placebo effect.
Experimental protocol

On the morning of the experimental trial, an 18G polyethylene catheter was inserted into a vein in the antecubital space in order to begin the primed, constant
infusion (~ 10 h) of L-[ring-13C6] phenylalanine and
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L-[15N] phenylalanine (Sigma-Aldrich, St. Louis, MO,
USA). A background blood sample was taken prior to
commencement of the isotope infusion. The priming
dose for the labeled phenylalanine was 2 μmol∙kg−1 while
the infusion rate was 0.05 μmol kg−1 min−1. A retrograde
catheter was inserted into a heated hand vein on the contralateral arm so that arterialized blood may be taken for
sampling. Muscle biopsies were performed on the lateral aspect of the vastus lateralis for the determination
of resting mixed muscle fractional synthesis rate (FSR) at
2 h and 4.5 h following stable isotope infusion initiation.
All biopsies were taken with a 5 mm Bergström biopsy
needle under sterile procedure and local anesthesia (1%
lidocaine). The EAA beverage was consumed following the second biopsy with biopsies three and four performed 60 min and 120 min post ingestion respectively
in order to measure post EAA mTORC1 signaling and
protein synthesis. A single incision was used for both pre
EAA muscle biopsies while a second incision was used
for the two post EAA biopsies. Multiple sampling from
the same area was limited by separating the incisions
by ~ 7 cm. Biopsies taken from the same incision were
angled ~ 5 cm from the previous one. This method has
been utilized in both our lab [21, 22] and as well as others
[23, 24]. Muscle tissue was immediately blotted, frozen in
liquid nitrogen and stored at − 80 °C until analysis. Blood
samples were collected during the resting (0, 89, 95, 105,
115, 125, 135, 150 min) and post-ingestion (0, 15, 30, 45,
60, 75, 90, 105, 120 min) time periods for the determination of blood L-[ring-13C6] phenylalanine enrichment and
amino acid concentrations. The infusion study concluded
with the fourth muscle biopsy at which time the participants were fed a standard meal.
Essential amino acid beverage

The EAA beverage was consumed following biopsy two.
The ingested EAA were dissolved in 300 mL of Fresca®
and enriched (8%) with L-[ring-13C6] and L-[15N] phenylalanine to maintain isotopic steady state in arterialized blood. The composition of the beverage is shown in
Table 2.
Muscle protein turnover

Enrichments of free L-[ring-13C6]Phenylalanine, and
L-[15N]Phenylalanine in blood and tissue fluid were
measured by gas chromatography–mass spectrometry (GC–MS) after addition of appropriate internal
standards and precipitation of blood and tissue proteins with sulfosalycilic acid, extraction with cation
exchange chromatography, and tert-butyldimethylsilyl
derivatization (t-BDMS). Correction for skewed isotopomer distribution and overlapping spectra were
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Fig. 2 Schematic of randomized experimental protocol. Participants ingested 10 g EAA following biopsy two. The small arrows represent blood
draws whereas the large arrows represent biopsies. EAA, essential amino acids. FSR, fractional synthesis rate. FBR, fractional breakdown rate. n = 7
(CON), 7 (CHQ)

Table 2 Composition of the essential amino acid solution
% of total

Grams (g)

Histidine

11

1.1000

Isoleucine

10

1.0000

Leucine

18

1.8500

Lysine

16

1.5500

Methionine

3

0.3000

Phenylalanine

16

1.5500

Threonine

14

1.4500

Valine

12

1.2000

performed as previously described [24]. The incorporation of L-[ring-13C6]Phenylalanine in the mixed muscle proteins was measured after protein extraction and
hydrolysis, amino acid extraction with cation exchange

chromatography, TBDMS derivatization, and GC–MS
analysis [25, 26].
Calculation of muscle protein synthesis

Muscle proteins and intracellular free amino acids were
extracted from biopsy samples as previously described
[21]. Bound muscle and intracellular free concentrations were calculated with the internal standard method
using tracer enrichments for L-[ring-13C6] phenylalanine,
L-[15N] phenylalanine and appropriate internal standards
via GC–MS (6890 Plus CG, 5973N MSD, 7683 autosampler, Agilent Technologies, Palo Alto, CA). Measurements were determined as previously described [24, 26].
Mixed-muscle protein-bound phenylalanine enrichment
was analyzed by GCMS after protein hydrolysis and
amino acid extraction, [27] using the external standard
curve approach [28]. The FSR of mixed muscle proteins
was calculated from the incorporation rate of L-[ring13
C6] phenylalanine into the mixed muscle proteins, and
the free-tissue phenylalanine enrichment where ΔEP/t is
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the slope of the straight line that fits the protein-bound
phenylalanine enrichment across two sequential biopsies, t is the time interval encompassing the two biopsies, EM(1), and E
 M(2) are the phenylalanine enrichments
(tracer/tracee) in the free muscle pool in the two biopsies. The results are presented as %/h. Phenylalanine is
used because it is an essential amino acid that is not oxidized in the muscle tissue. Thus, phenylalanine utilization in the muscle is an index of muscle protein synthesis
seen in the following equation:

FSR = (�Ep /t)/[(EM(1) + EM(2) )/2] · 60 · 100

Calculation of muscle protein breakdown

Muscle protein fractional breakdown rate (FBR) was
measured with phenylalanine tracers using the precursor-product method [24]. The method requires measurement of intracellular free phenylalanine enrichment at
steady-state and after 1 h of tracer decay. Frequent arterialized blood sampling during that 1 h period is necessary
for tracking the decay of blood enrichment. To measure
FBR at baseline, the L-[ring-13C6] phenylalanine enrichment at 4 h was used as the plateau enrichment and
L-[15N] Phenylalanine enrichment at 4 h was used for
the 1 h decay enrichment. FBR was calculated using the
formula:
FBR = �EM /[p



EA (t)dt − (1 + p)



EM (t)dt] · (QM /T )

where EA(t) and EM(t) are the arterialized and muscle
free enrichments at time t, and t1 and t2 are two time
points. P = EM/(EA − EM) at plateau, EA and EM are
enrichments in the arterial pool and muscle intracellular
pool, respectively, and QM/T is the ratio of free to bound
phenylalanine in muscle.
Whole body proteolysis

Whole body proteolysis was measured by dividing the
L-[ring-13C6] phenylalanine tracer infusion rate by the
blood L-[ring-13C6] phenylalanine enrichment (tracer to
tracee ratio) at each given time point [29].
Western blot analysis

Phosphorylation of mTORC1, 4E-BP1, S6K1, and rpS6
was measured using western blot techniques as previously described [22]. 50 μg of protein from each sample
was loaded in duplicate onto a 7.5% or 15% polyacrylamide gel (Criterion; Bio-Rad) and subjected to electrophoresis at 150 V for 70 min. Following electrophoresis,
proteins were transferred to a polyvinylidene difluoride
membrane (Bio-Rad) that were then blocked in 5%
non-fat dried milk. Membranes were incubated with a

primary antibody overnight at 4 °C. The following rabbit
polyclonal primary antibodies (Cell Signaling, Beverley,
MA) were used: mTOR (Ser2448), S6K1 (Thr389), 4EBP1
(Thr37/46), and ribosomal protein S6 
(Ser240/244). Blots
were incubated with secondary antibody (Amersham
Bioscience) washed, and then a chemiluminescent solution (ECL plus; Amersham BioSciences, Piscataway, NJ,
USA) was administered. Optical density measurements
were then obtained with a digital imager (Bio-Rad) so
that a densitometric analysis (Quantity One software,
version 4.5.2; Bio-Rad) could be performed. Following detection of the phosphorylated protein, blots were
stripped of primary and secondary antibodies and then
re-probed for other proteins. All data is expressed relative to the internal standardized rodent skeletal muscle
control used to normalize across blots.
Cell culture

Murine C2C12 myoblasts were obtained from American
Type Culture Collection (Manassas, VA) and cultured
on 0.1% gelatin‐(Sigma‐Aldrich, St. Louis, MO) coated
6-well cultureware plates in growth media (high‐glucose
Dulbecco’s modified Eagle medium supplemented with
10% fetal bovine serum, 50 U of penicillin/mL, 50 μg of
streptomycin/mL; Invitrogen, Carlsbad, CA). The cells
were incubated in an atmosphere of 5% CO2/95% air
at 37 °C. At ~ 90% confluency, differentiation medium
(low‐glucose Dulbecco’s modified Eagle medium supplemented with 2% horse serum, 50 U of penicillin/mL,
50 μg of streptomycin/mL; Invitrogen, Carlsbad, CA) was
added to cultures for approximately 5 days to allow for
formation of multinucleated myotubes.
Cell culture experimental design
mTORC1 signaling

At the outset of the experiment, myotubes were nutrient starved for 8 h in starvation media of HEPES‐buffered saline with no leucine (HBS, 20 mmol/L HEPES/
Na, 140 mmol/L NaCl, 2.5 mmol/L MgSO4, 5 mmol/L
KCl, and 1 mmol/L CaCl2; pH 7.4; Sigma‐Aldrich). For
each 6-well plate, two wells were designated “control
(Con)” and allowed to be starved for an additional 70 min
in starvation media for a total of 9 h and 10 min. Two
wells were designated “leucine only (Leu)”. These wells
were starved for a total of 9 h and then administered
1 mM leucine for 10 min. Lastly, two wells were designated “chloroquine plus leucine (Chq + leu)”. These wells
were nutrient starved for 8 h and then administered
2 mg/ml chloroquine for 60 min followed by 1 mM leucine treatment for 10 min. The experimental procedure
was repeated to reach a sample size of eight per group.
All wells were washed with PBS between all treatment
administrations. This specific protocol was developed
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as a result of extensive pilot testing in order to properly
optimize these experimental conditions. The 2 mg/ml
dose was chosen following MTT cell viability assays.
Following treatments, myotubes were rinsed with
PBS and each well scraped in ice‐cold extraction buffer
(50 mmol/L Tris‐HCl, 250 mmol/L mannitol, 50 mmol/L
NaF, 5 mmol/L Na pyrophosphate, 1 mmol/L EDTA,
1 mmol/L EGTA, 1% Triton X‐100, 1 mmol/L DTT,
1 mmol/L benzamidine, 0.1 mmol/L PMSF, 5 μg/mL soybean trypsin inhibitor, pH 7.4). Samples were frozen in
liquid nitrogen until analyzed.
To determine protein concentration, samples were
thawed and vortexed three times and later sonicated for
15 s. Protein concentrations were calculated using the
Bradford Protein Assay (Smartspec Plus, Bio‐Rad, Hercules, CA).
Myotube protein synthesis

MyPS was measured using the surface sensing of translation (SUnSET) technique as described by Goodman [30].
Cells were designated into two conditions, “nutrient rich”
and “nutrient starve”. Within each condition, one subset
was administered chloroquine while the other was not
and thus served as controls. For the starvation conditions, myotubes were starved and treated as described
above for mTORC1 signaling with the exception of no
leucine administration. Thus nutrient starve control cells
were starved for 9 h in starvation media. Nutrient starve
chloroquine cells were starved in starvation media for
8 h, then for an additional hour in starvation media with
2 mg/ml chloroquine. Cells were then administered 1 µM
puromycin (Thermo Fisher Scientific, Wilmington, DE)
for 30 min and collected as described above. The nutrient rich condition entailed a 16 h serum starve (no horse
serum) in low glucose DMEM followed by a 1 h starvation in HEPES‐buffered saline containing 2 mg/ml chloroquine for cells in that subgroup. Cells were then put
back into DMEM while provided 1 µM puromycin for
30 min and subsequently collected. The experimental
procedure was repeated to reach a sample size of six per
group. The experimental procedure here differs from the
mTORC1 signaling procedure due to technical limitations. It was not possible to detect a difference between
control and a 10 min 1mM leucine administration using
this method. We believe that a 1 mM bolus of leucine can
result in mTORC1 pathway phosphorylation, yet it is not
sufficient to promote activation of protein synthesis at a
level necessary for detection. This is most likely due to
the limited availability of amino acids required for generating new proteins as these cells are starved for 9 h with
no amino acids and then given only leucine. Therefore a
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serum starve in low glucose DMEM was used to provide
those amino acids in the nutrient rich groups.
Western blot analysis

Cell lysates were diluted (1:1) in a 2 × sample buffer mixture (125 mmol/L Tris, pH 6.8, 25% glycerol, 2.5% SDS,
2.5% β‐mercaptoethanol, and 0.002% bromophenol blue)
and then boiled for 3 min at 100 °C. Equal amounts of
total protein were loaded into each lane, and the samples
were separated by electrophoresis at 150 V for 60 min on
a 7.5% polyacrylamide gel (Criterion, Bio‐Rad). All samples were loaded in duplicate with a loading control and
molecular weight ladder (Precision Plus, Bio‐Rad).
Following electrophoresis, the protein was transferred
to a polyvinylidene difluoride membrane (Bio‐rad) at
50 V for 60 min. Blots were blocked in 1% bovine serum
albumin for 1 h for mTORC 1 signaling proteins or
30 min for puromycin and then incubated with primary
antibody overnight at 4 °C. The following rabbit polyclonal primary antibodies for mTORC1 signaling (Cell
Signaling, Beverley, MA) were used, mTOR (Ser2448)
and S6K1 (Thr389). The primary antibody for puromycin protein synthesis was the mouse IgG2a monoclonal
anti-puromycin antibody clone 12D10 (EMD Millipore,
Billerica, MA).The following morning, secondary antibody (Amersham Bioscience Piscataway, NJ for mTOR
signaling), or horseradish peroxidase conjugated antimouse IgG Fc 2a antibody (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA, USA for puromycin
protein synthesis) was added for 1 h at room temperature. Blots were incubated in a chemiluminescent solution (ECL plus, Amersham BioSciences,) for 5 min and
optical density measurements quantified using a digital
imager (ChemiDoc, Bio‐Rad) and densitometric analysis
was performed using Quantity One 4.5.2 software (Bio‐
Rad). Membranes were stripped using Restore Western
Blot Stripping buffer (Pierce Biotechnology, Rockford,
IL). Phosphorylation values were normalized to the loading control.
Statistical analysis

All values are expressed as Mean ± SEM. Cell culture
experimental data were modeled with t-tests to test differences between groups. Clinical trial data were transformed using the Box-Cox set of transformations to
stabilize the variance and make the data approximately
normally distributed. To test differences between groups,
the data were modeled using an ANCOVA model with
resting/baseline values as a covariate. The testing of differences was thus accomplished through a t-test of the
parameter indicating the difference between groups.
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Fig. 3 Blood and Muscle Amino Acid Concentrations. Changes from
rest in blood Leucine (A), muscle Leucine (B), blood Phenylalanine (C),
and muscle Phenylalanine (D) at baseline and following ingestion of
a 10 g EAA beverage. Data are mean ± SEM. N = 7 for both treatment
groups. “a” different from resting values, P < 0.05. “b” difference
between 1 h post and 2 h post, “c” difference between treatment
groups, P < 0.05. CON, control. CHQ, chloroquine

Comparisons with resting values were based on testing
contrasts across time using a mixed model with subject
as a random intercept term. All baseline comparisons
were done using two-group t-tests. Fold changes were
tested against baseline using a one-sample t-test. Significance was set at P < 0.05. All calculations were done in R
version 13.2 [31].

Results
Clinical trial
Subject characteristics

Descriptive characteristics for all subjects are shown in
Table 1. The participants in both groups displayed similar lean mass, percent body fat and BMI (P > 0.05). The
consort diagram for clinical trial enrollment is shown in
Fig. 1.
Blood and muscle amino acid concentrations

Blood concentrations for leucine (Fig. 3A) were elevated
from baseline (P < 0.05) for both treatment groups 60 min
post ingestion. Leucine intracellular muscle concentrations were elevated in both groups at 1 h and at 2 h
post ingestion compared to baseline (P < 0.05) while 1 h
post ingestion was significantly different (P < 0.05) than
2 h post ingestion for both groups (Fig. 3B). There was
no difference between groups for either leucine measure (P > 0.05). Phenylalanine concentrations in the blood
were elevated from baseline (P < 0.05) for CON from 30
to 120 min post ingestion and CHQ from 15 to 90 min
post ingestion (P < 0.05) (Fig. 3C). Phenylalanine intracellular muscle concentrations were elevated in both groups
at 1 h and at 2 h post ingestion compared to baseline
(P < 0.05) while 1 h post ingestion was significantly higher
than 2 h post ingestion for both groups (Fig. 3D). There
was no difference between groups for either phenylalanine measure.
Muscle mTORC1 signaling

The phosphorylation status of mTORC1 (Ser2448)
was significantly increased (P < 0.05) at 1 h post ingestion in both groups compared to baseline with only
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Fig. 4 Muscle mTORC1 Signaling. Western blot analyses of mTORC1 (A) and mTOR pathway-related proteins: S6K1 (B), 4EBP1 (C) and rpS6 (D), at
baseline and following a 10 g EAA beverage. Data are mean ± SEM. N = 7 for both treatment groups. *Different from pre, P < 0.05. #trend difference
from pre, P = 0.07. CON, control. CHQ, chloroquine

CON significantly elevated at 2 h compared to baseline
(Fig. 4A). S6K1 (Thr389) phosphorylation was elevated at
1 h post ingestion for both groups. At 2 h post ingestion,
CHQ showed a trend for increased S6K1 phosphorylation of P = 0.07 compared to baseline (Fig. 4B). 4E-BP1
(Thr37/46) phosphorylation was significantly increased
(P < 0.05) at 1 h post ingestion in both groups compared

to baseline. CON 4E-BP1 phosphorylation was significantly elevated at 2 h compared to baseline (Fig. 4C). The
phosphorylation status of rpS6 (Ser240/244) was significantly increased (P < 0.05) at 1 h post ingestion in both
groups compared to baseline. Only CON rpS6 phosphorylation was significantly elevated at 2 h compared
to baseline (Fig. 4D). There were no differences in total
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protein abundance between groups at any time point for
all measured proteins (P > 0.05).
Fractional synthetic rate

There was no difference between groups for muscle protein synthesis at any time point (P > 0.05). Post
EAA ingestion FSR was elevated from resting values
for CHQ (P < 0.05) while CON showed a trend for an
increase P = 0.06 (Fig. 5).
Fractional breakdown rate

There was no difference (P > 0.05) between groups for
muscle protein breakdown at rest (Fig. 5).
Whole body proteolysis

There was no difference between groups at any time
point (P > 0.05). Whole body proteolysis was significantly
decreased from baseline in CON following EAA ingestion (P < 0.05) (Fig. 5).
Cell culture experiments
Myotube mTORC1 signaling and protein synthesis

The phosphorylation status of mTORC1 (Ser 2448) was
significantly increased with 1 mM leucine administration
(P < 0.05) compared to control and chloroquine + leucine (Fig. 6A). The phosphorylation status of S6K1
(Thr389) was significantly increased with 1 mM leucine
administration (P < 0.05) compared to control and chloroquine + leucine (Fig. 6B). MyPS was reduced in the
presence of chloroquine for both the nutrient rich and
nutrient starved conditions (P < 0.05) compared to their
respective controls. There was no difference in protein
synthesis between the two control conditions (nutrient
rich vs. nutrient starve) (P = 0.095) nor was there a difference between control in the nutrient starvation state
and chloroquine in the nutrient rich state (P = 0.478).
Nutrient rich control was different compared to nutrient
starved chloroquine (P < 0.05) (Fig. 6C).

Fig. 5 Fractional Synthetic Rate, Fractional Breakdown Rate, and Whole
Body Proteolysis. A FSR (vastus lateralis) at baseline and for the two hour
period post ingestion of the 10 g EAA beverage. Data are mean ± SEM.
N = 7 for both treatment groups. *Different from rest, P < 0.05. #trend
difference from pre, P = 0.06. FSR, fractional synthesis rate. CON, control.
CHQ, chloroquine. EAA, essential amino acids. B FBR (vastus lateralis)
for the 1 h period prior to ingestion of the 10 g EAA beverage. Data
are mean ± SEM. N = 7 for both treatment groups. FBR, fractional
breakdown rate. CON, control. CHQ, chloroquine. C Whole body
proteolysis at baseline and for the two hour period post ingestion of
the 10 g EAA beverage. Data are mean ± SEM. N = 7 for both treatment
groups. *Different from pre, P < 0.05. CON, control. CHQ, chloroquine

Discussion
We conducted an in vivo human clinical trial wherein
we administered chloroquine prior to ingesting essential
amino acids to test the effect of chloroquine on mTORC1
signaling and protein synthesis. We found no effect of
chloroquine on either outcome measure following EAA
ingestion during the clinical trial.
The nutritional benefits of amino acid supplementation in humans have been investigated for many decades
going at least as far back as the 1940s [32]. Since that
time, it has become understood that amino acids promote protein synthesis [33]. Yet the mechanism(s) underlying amino acid activation of protein synthesis have
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(See figure on next page.)
Fig. 6 Myotube mTORC1 signaling and protein synthesis. Cells were starved for 8 h in HEPES-buffered saline. Control was starved for an additional
70 min in fresh HEPES. “Leucine” was starved for 60 min in fresh Hepes and 10 min in fresh Hepes with leucine. “Chloroquine + leucine” was starved
in fresh HEPES with chloroquine for 60 min and 10 min in fresh HEPES with leucine. A Phosphorylation of mTORC1 at Ser 2448 in control, leucine
(1 mM for 10 min), and chloroquine + leucine (2 mg/ml chloroquine for 60 min followed by 1 mM leucine for 10 min) conditions. Insert shows
representative western blot for each condition. B Phosphorylation of S6K1 at Thr 389 (same conditions). Insert shows representative western blot for
each condition. Data are mean ± SEM. N = 8 for both treatment groups. *Different from control, P < 0.05. &Different from chloroquine + leucine. Chq,
chloroquine. C Western blot analyses of protein synthesis using the SUnSET technique. Nutrient Rich-Control and Chloroquine were serum starved
for 16 h and nutrient starved for 1 h (2 mg/ml for Chloroquine group only) prior to 30 min puromycin (1 µM) exposure. Nutrient Starve groups were
starved under the same conditions as described above for mTORC1 signaling prior to 30 min puromycin (1 µM) exposure. Data are mean ± SEM,
N = 6. abcColumns with uncommon letters differ, P < 0.05

been elusive until recently. Work in HEK cells has demonstrated the necessity of the interaction of the lysosome
with the mTOR complex via a complex named Ragulator.
The Ragulator protein complex resides on the surface of
the lysosome. In the presence of amino acids, Ragulator
recruits the Rag proteins in their GTP-bound state to the
lysosomal membrane in order to dock with the mTOR
complex and initiate mTOR signaling [34, 35]. A year
later, [10, 36] revealed an additional component of amino
acid sensing, the vacuolar H( +)-adenosine triphosphatase ATPase (v-ATPase). The v-ATPase was shown to
provide a critical interaction with the scaffolding protein
Ragulator during amino acid activation of mTOR signaling [36]. Other players in the amino acid sensing mechanism have since been identified. GATOR1 is an inhibitor
of this pathway as it acts on the GTP-bound Rag proteins.
GATOR2 works to inhibit GATOR1 in the presence of
amino acids. Lastly the Sestrins are a family of proteins
that interact with GATOR2 and are necessary for the
colocalization of the lysosome and mTOR [37].
As all of the research described above was conducted
in kidney cells, this current study sought to test the
conservation of this amino acid sensing mechanism in
human skeletal muscle. Settembre et al. [38] demonstrated reduced mTOR signaling with the inhibition of
downstream target S6K1 using the drug chloroquine
[38]. Chloroquine is a lysosomotropic agent that raises
the internal pH of the lysosome. This change in pH
causes lysosomal dysfunction and inhibition of lysosomal protein degradation [39]. Yu and Long [40] also
demonstrated lysosomal/autophagy dysfunction through
chloroquine administration in C212 cells [40]. This inhibition resulted in a reduction in mTOR signaling under
starvation conditions and an increase in signaling with
amino acid supplementation, in the presence of chloroquine, although the treatment included thirteen separate
amino acids [40].
To test the role of the lysosome in amino acid sensing
in human muscle, we conducted a human trial utilizing
a 10 g EAA solution that has been shown to enhance
mTORC1 signaling and muscle protein synthesis during previous studies [17, 41]. We found that chloroquine

administration did not alter amino acid concentrations
in the blood following EAA ingestion and did not inhibit
mTORC1 activation. Similarly chloroquine administration did not prevent the EAA-induced increase in muscle protein synthesis in our human subjects. Therefore,
we could not confirm the validity of amino acid sensing
through the lysosome in humans from this study. We also
examined muscle protein breakdown and proteolysis to
determine whether any chloroquine-mediated effects
were present. Previous work has shown that a 750 mg
dose of chloroquine (the dose used in the current study)
is sufficient to reduce whole body proteolysis in humans
[20]. In our study, we also found that the rate of whole
body proteolysis was numerically less in the chloroquine
group (e.g., 0.71 v 0.79 μmol/kg/min) at baseline, but this
difference did not reach statistical significance. Amino
acids have been shown to reduce both whole body as
well as muscle protein breakdown [42, 43], and our data
showed a similar response in the control group. Interestingly, whole body proteolysis did not drop in response to
EAA ingestion for the chloroquine group as it did for the
control group which may indicate that chloroquine was
having an impact on whole body proteolysis. Nevertheless, muscle protein breakdown was not altered by chloroquine in our samples. Similarly Barrett et al. did not
witness a change in skeletal muscle protein breakdown
during a 3 h chloroquine infusion into the forearm of
human subjects [44]. Therefore, we are able to surmise
two potential explanations for these results. The first is
that inhibition of the lysosome by chloroquine can inhibit
mTORC1 signaling and FSR in skeletal muscle as hypothesized, but the dosage of chloroquine used in our study
was not sufficient to alter muscle protein turnover. Chloroquine is known to accumulate in certain tissues of the
body, specifically the liver, spleen, kidney and lung. These
organs were found to have chloroquine concentrations
200–500 times that found in the blood [45]. Therefore, it
is possible that the dosage for this study was insufficient
to reach the levels necessary to interrupt lysosomal function within skeletal muscle. That would help to explain
the disparity between our results at the whole body level
versus at the muscle specific level as well as differences
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between earlier studies performed in various cell lines,
and our study performed in humans. A second possibility
is that lysosomal disruption within human skeletal muscle does not alter mTORC1 signaling and muscle protein
turnover following amino acid ingestion in vivo. It is possible that mTORC1 signaling may remain intact following
lysosomal disruption by an amino acid sensing mechanism that is independent of the lysosome in humans.
We acknowledge the chloroquine dosing as a limitation,
however, administering larger doses was not an option
as that would have been considered unsafe to our participants (as determined by our study physician and local
institutional review board).
Following completion of the clinical trial, we conducted
in vitro experiments to test the effect of chloroquine on
mTORC1 signaling and protein synthesis in C2C12 myotubes. We found an increase in both mTORC1 and S6K1
phosphorylation following ten minutes of 1 mM leucine administration. This increase was not seen in cells
provided 2 mg of chloroquine for 1 h prior to leucine
administration. Therefore it would appear that mTORC1
signaling is potentially hampered in muscle cells in
the presence of chloroquine. While it is not possible to
determine if lysosomal disruption is the sole cause of
this diminished signaling, it does provide evidence that
is comparable to that seen by others mentioned above
[38, 40]. Protein synthesis was reduced by chloroquine
regardless of nutrient condition. Therefore, we can tentatively conclude from these data that this mechanism of
amino acid sensing (i.e., mTORC1 translocation to the
lysosomal membrane in response to amino acid availability) is conserved in C2C12 skeletal muscle cells.

Conclusions
In conclusion, chloroquine did not inhibit amino acidinduced activation of mTORC1 signaling and skeletal
muscle protein synthesis in humans as it does in C2C12
muscle cells. Therefore, different in vivo experimental
approaches are required for confirming the precise role
of the lysosome and amino acid sensing in human skeletal muscle.
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